Introduction {#s1}
============

The most severe form of malaria in humans is caused by *P. falciparum* with approximately 214 million cases and over 450,000 deaths each year occurring mostly in subtropical and tropical regions of the world ([@bib40]). Infection of humans occurs during blood feeding by a female Anopheles mosquito. The injected parasites migrate to the liver, and after development in hepatocytes liver merozoites are released that quickly invade erythrocytes in the circulating blood. The parasites grow and divide to produce 16 to 32 new daughter merozoites. Following egress from the host cell, these daughter cells invade new erythrocytes perpetuating the asexual blood stage life cycle that is responsible for the symptoms of malaria.

Invasion of human erythrocytes by *P. falciparum* merozoites involves multiple interactions of ligands with host receptors in a complex multistep process that ultimately ends with the internalization of the parasite (reviewed in \[[@bib8]\]). The initial interaction of the parasite with the erythrocyte membrane is driven by low affinity interactions involving surface proteins that facilitate apical reorientation. This is followed by high-affinity binding of specific host receptors to the erythrocyte binding-like (EBL) and reticulocyte binding-like homologues (PfRh or PfRBP) ligand families to specific host receptors (reviewed in ([@bib8]). The PfRh ligands are large proteins, released onto the surface of the merozoite and required for activation of downstream invasion events ([@bib29], [@bib30]; [@bib36]; [@bib34], [@bib35]). PfRh5 is a disparate member of the PfRh family of ligands because, unlike other members of this protein family, it is small and lacks a transmembrane domain ([@bib17]; [@bib3]). PfRh5 binds to basigin on the erythrocyte surface ([@bib12]). The crystal structures of PfRh5 alone ([@bib6]) and in complex with its receptor basigin ([@bib42]) have been determined and the Rh domain shown to exhibit a novel fold.

PfRh5 forms a complex with cysteine-rich protective antigen (CyRPA) and *P. falciparum* Rh5 interacting protein (PfRipr) ([@bib4]; [@bib31]; [@bib38]). The function of PfRh5 is essential and blocking of its interaction with basigin using either soluble basigin or specific antibodies inhibits merozoite invasion ([@bib38]; [@bib39]). Furthermore, *P. falciparum* merozoites in which the *cyrpa* or *pfripr* genes have been conditionally disrupted also cannot invade human erythrocytes and this process is blocked at the same point as observed when PfRh5 function is inhibited ([@bib38]). The function of the PfRh5/CyRPA/PfRipr complex has been associated with the formation of a discontinuity or pore between the merozoite and the erythrocyte that allows movement of Ca^2+^ into the host cell. It has also been hypothesized that this protein complex may be directly or indirectly involved in transfer of proteins into the host cell ([@bib38]; [@bib39]). Regardless of the specific mechanisms at play, the PfRh5/CyRPA/PfRipr complex plays a pivotal role in the sequential molecular events leading to merozoite invasion of erythrocytes.

CyRPA and PfRipr are localized in the micronemes whereas PfRh5 is present at the neck of the rhoptries and these proteins are released onto the surface during merozoite invasion ([@bib38]). Super-resolution microscopy has shown that the tripartite complex forms only at the interface between the invading parasite membrane and the erythrocyte membrane, with pools of PfRh5, CyRPA and PfRipr spread over the surface of the merozoite ([@bib38]). The PfRh5/CyRPA/PfRipr complex is tightly associated with the membrane, and previous evidence suggested that CyRPA has a glycophosphatidylinositol (GPI) membrane anchor and is responsible for the association of the complex with the merozoite membrane ([@bib31]). However, it was subsequently shown that CyRPA does not have a GPI anchor, and, as none of these proteins have a transmembrane domain, it remains unclear how they associate with the parasite's plasma membrane ([@bib38]).

Antibodies to PfRh5, PfRipr and CyRPA inhibit merozoite invasion and these proteins are important blood stage malaria vaccine candidates ([@bib4]; [@bib14]; [@bib41]; [@bib27]; [@bib32]). CyRPA-specific monoclonal antibodies inhibit growth of *P. falciparum* in a NOD-scid IL2Ry^null^ mice engrafted with human erythrocytes ([@bib15]). Additionally, a PfRh5-based vaccine has been shown to be efficacious in *P. falciparum* challenged aotus monkeys ([@bib13]).

To understand the molecular basis for blocking of CyRPA function by antibodies, we have co-crystallized this protein with a Fab fragment obtained from an invasion inhibitory monoclonal antibody. We have determined the crystal structure of this complex using diffraction data to 2.44 Å resolution and shown that CyRPA has a six-bladed β-propeller fold. We have also determined the structure of the uncomplexed CyRPA using data to 3.09 Å resolution. Together, these structures have enabled elucidation of the structural basis for antibody-mediated inhibition of CyRPA-enabled *P. falciparum* merozoite invasion.

Results {#s2}
=======

Recombinant expression of functional CyRPA {#s2-1}
------------------------------------------

Full-length mature CyRPA (residues 30--362 of the translated protein product) was expressed in insect cells and purified to homogeneity as evidenced by size-exclusion chromatography (SEC) and SDS-PAGE analysis ([Figure 1A](#fig1){ref-type="fig"}). Whilst CyRPA has been shown to form a co-complex with PfRh5 and PfRipr ([@bib31]; [@bib38]), it is not known with which of these two proteins it associates. To determine if the recombinant CyRPA can bind to PfRh5 ([@bib6]), we combined the two proteins and showed by SEC they are capable of forming a stable 1:1 complex. In these experiments, PfRh5 was incubated with excess CyRPA and the stable CyRPA/PfRh5 complex eluted ahead of free CyRPA ([Figure 1B](#fig1){ref-type="fig"}). CyRPA/PfRh5 complex formation was also confirmed by incubation of excess CyRPA with FLAG-tagged PfRh5 followed by immunoprecipitation with anti-FLAG antibodies. In these experiments, CyRPA co-precipitated with PfRh5 ([Figure 1C](#fig1){ref-type="fig"}). Together with the SEC result, this finding suggests an association between CyRPA and PfRh5 within the PfRh5/CyRPA/PfRipr complex during merozoite invasion. These experiments also indicate that our recombinant CyRPA is correctly folded and also functionally competent.10.7554/eLife.21347.002Figure 1.Production of functional recombinant CyRPA.(**A**) Purified recombinant CyRPA was analysed by size exclusion chromatography and SDS-PAGE. (**B**) Formation of the PfRh5/CyRPA complex was monitored by size exclusion chromatography, CyRPA formed a complex with Rh5 and the complex was eluted in the peak labelled as Rh5/CyRPA. The chromatographic profiles are shown (top panel) and fractions eluted from the column (lower panel) were analysed by SDS-PAGE. (**C**) Immunoprecipitation of FLAG-PfRh5 after incubation with CyRPA. Cy-unb, CyRPA alone; Cy-eluted, elution from anti-FLAG antibody beads of CyRPA alone; Rh5/Cy-unb, FLAG-PfRh5 and excess CyRPA incubated and unbound protein analysed; Rh5/Cy-elu, FLAG-PfRh5 and CyRPA eluted from anti-FLAG antibody beads.**DOI:** [http://dx.doi.org/10.7554/eLife.21347.002](10.7554/eLife.21347.002)

CyRPA-specific invasion inhibitory monoclonal antibodies block interaction of CyRPA with PfRh5 {#s2-2}
----------------------------------------------------------------------------------------------

Monoclonal antibodies were raised to recombinant CyRPA and their ability to inhibit *P. falciparum* growth was determined. Three monoclonal antibodies (5B12, 3D1 and 8A7) were identified that inhibited growth to approximately 70% at 2 mg/ml, whereas others (7A6 and 8B9) showed essentially no inhibition ([Figure 2A](#fig2){ref-type="fig"}). Immunoblot analysis of CyRPA with the monoclonal antibodies showed those that blocked parasite growth reacted with a conformational epitope as they bound to non-reduced protein but not to reduced protein ([Figure 2B](#fig2){ref-type="fig"}). In contrast, the antibodies that did not inhibit parasite growth reacted with both reduced and non-reduced CyRPA, consistent with them binding to a linear epitope. The three inhibitory anti-CyRPA monoclonal antibodies (5B12, 3D1 and 8A7) have a similar potency as the inhibitory anti-Ripr monoclonal antibody 5G6 in the growth inhibition assays ([Figure 2A](#fig2){ref-type="fig"}).10.7554/eLife.21347.003Figure 2.Anti-CyRPA monoclonal antibodies inhibit *P. falciparum* growth and interaction of PfRh5.(**A**) In vitro growth inhibition (GIA) assays were performed to assess the abilities of the monoclonal antibodies raised against recombinant CyRPA to block *P. falciparum* parasite growth in human erythrocytes. Assays were performed twice in triplicate and error bars denote SD of the mean of 6 values. Anti-Rh5 mAb 4G4 (not inhibitory) and anti-Ripr mAb 5G6 (inhibitory) are included as GIA controls. (**B**) Immunoblot of inhibitory (8A7) and non-inhibitory (7A6) monoclonal antibodies against proteins from CyRPA-HA tagged transgenic *P. falciparum* schizonts in reduced (R) and non-reduced (NR) condition. The *P. falciparum* parasites expressed haemagglutinin-tagged CyRPA protein. (**C**) Monoclonal antibody 8A7 blocked binding of PfRh5 to CyRPA. PfRh5 and CyRPA were incubated together with 8A7 and the complex formation monitored by size exclusion chromatography and SDS-PAGE analysis under non-reducing conditions. Monoclonal antibody 8A7 bound to CyRPA, preventing the PfRh5/CyRPA complex formation. CyRPA was co-eluted with 8A7 in the earlier fractions and the free Rh5 eluted in the later fractions. (**D**) Monoclonal antibody 7A6 did not inhibit the formation of the PfRh5/CyRPA complex as monitored by size exclusion chromatography and SDS-PAGE analysis. This antibody did not bind to native CyRPA indicating the linear epitope is not surface exposed. (**E**) Non-inhibitory anti-PfRh5 monoclonal antibody 4G4 did not significantly inhibit the formation of the PfRh5/CyRPA complex. The PfRh5/CyRPA complex bound to antibody 4G4 and was eluted together with 4G4 as a tri-molecule complex in the earlier fractions.**DOI:** [http://dx.doi.org/10.7554/eLife.21347.003](10.7554/eLife.21347.003)

To determine the growth-inhibitory mechanism of the monoclonal antibody 8A7, we performed experiments to examine if the antibody blocked the interaction of CyRPA with PfRh5 ([Figure 2C](#fig2){ref-type="fig"}). Both proteins were incubated together in the presence of either inhibitory monoclonal antibody 8A7 or non-inhibitory monoclonal antibody 7A6. The mixtures were analysed by SEC and fractions visualized on SDS-PAGE and stained with Coomassie Blue R250 ([Figure 2C and D](#fig2){ref-type="fig"}). In the presence of inhibitory monoclonal antibody 8A7, the formation of the PfRh5/CyRPA complex is disrupted with PfRh5 eluted alone in the later fractions ([Figure 2C](#fig2){ref-type="fig"}), and CyRPA eluted as a complex with 8A7 in the earlier fractions. However, in the presence of non-inhibitory monoclonal antibody 7A6, CyRPA remains bound to PfRh5 ([Figure 2D](#fig2){ref-type="fig"}). The antibody 7A6 also did not bind to native CyRPA consistent with binding to a linear epitope in immunoblots ([Figure 2B](#fig2){ref-type="fig"}) that is not exposed on the surface of the protein. In addition, in the presence of non-inhibitory anti-PfRh5 monoclonal antibody 4G4 ([Figure 2A](#fig2){ref-type="fig"}), the PfRh5/CyRPA complex remained largely intact and was eluted as a tri-molecular complex in the earlier fractions, with free CyRPA eluted in the later fractions ([Figure 2E](#fig2){ref-type="fig"}). These results suggested that growth-inhibitory mechanism of the monoclonal antibody 8A7 is likely due to the disruption of PfRh5/CyRPA complex formation.

The crystal structures of CyRPA alone and in complex with the Fab fragment of invasion inhibitory monoclonal antibody 8A7 {#s2-3}
-------------------------------------------------------------------------------------------------------------------------

We crystallized CyRPA in complex with a single 8A7 Fab fragment (see Methods). The structure of the complex was determined using diffraction data to 2.44 Å resolution by molecular replacement using a homologous Fab fragment to obtain initial phases, followed by iterative model building and crystallographic refinement ([Figure 3](#fig3){ref-type="fig"}). Crystals were also obtained of uncomplexed CyRPA; this structure was determined by molecular replacement, using the CyRPA component of the Fab-complexed structure as a search model, and subsequently refined using diffraction data to 3.09 Å resolution. Crystallographic data collection and refinement statistics for both structures are shown in [Table 1](#tbl1){ref-type="table"}.10.7554/eLife.21347.004Figure 3.The crystal structure of the uncomplexed CyRPA.(**A**) Orthogonal view of the ribbon representation of CyRPA, colored in rainbow fashion from the N-terminus (*blue*) through to the C- terminus (*red*). (**B**) Amino acid sequence and the secondary structure of CyRPA, showing the location of the 24 canonical strands of the six-bladed β-propeller \[labelled 'β*m*s*n*' where the index *n* denotes the strand and the index *m* the sheet (*n* = 1,..,4; *m* = 1,..,6)\]. (**C**) Assembly of the 222 pseudo-symmetric tetramer of CyRPA within the crystallographic asymmetric unit, showing the formation of the extended 5--5 and 6--6 sheets (*orange* and *red*, respectively). Each monomer of CyRPA in the asymmetric unit is labelled a, b, c, d.**DOI:** [http://dx.doi.org/10.7554/eLife.21347.004](10.7554/eLife.21347.004)10.7554/eLife.21347.005Figure 3---figure supplement 1.Comparison of CyRPA with *C.perfringens* NanI sialidase. Clustal Omega sequence alignment of *P. falciparum* CyRPA (without signal peptide) and the catalytic domain of *Clostridium perfringens* NanI sialidase ([@bib26]). These sequences share 16% identity and 33% similarity. Conserved sialidase features include Asp box motifs (*red* boxes), catalytic acid/base residue (*green*), catalytic nucleophile residue (*yellow*) and the acidic residue that modulates the nucleophile's pKa (*blue*).**DOI:** [http://dx.doi.org/10.7554/eLife.21347.005](10.7554/eLife.21347.005)10.7554/eLife.21347.006Figure 3---figure supplement 2.Recombinant CyRPA does not have sialidase activity.Hydrolysis of 4-methylumbelliferyl *N*-acetyl-α-D-neuraminic acid (4MU-NeuNAc) in the presence of bacterial sialidase (neuraminidase) from *Arthrobacter ureafaciens*, CyRPA or BSA at different pH values. These values, obtained in triplicate, were normalized with respect to the fluorescence measured for 10 μM 4-methylumbelliferone in glycine buffer (0.9 M, pH 10) to determine the completeness of each reaction.**DOI:** [http://dx.doi.org/10.7554/eLife.21347.006](10.7554/eLife.21347.006)10.7554/eLife.21347.007Table 1.Data collection and refinement statistics.**DOI:** [http://dx.doi.org/10.7554/eLife.21347.007](10.7554/eLife.21347.007)\
CyRPACyRPA/FabWavelength (Å)0.9540.954Resolution range (Å)36.45--3.09 (3.20--3.09)^\*^38.34--2.44 (2.53--2.44)Space groupP1P2~1~2~1~2~1~Unit cell* a*, *b*, *c* (Å)* α*, *β*, *γ* (°)\
68.7, 83.56, 95.3296.76, 104.11, 115.20\
79.95, 87.38, 145.1490, 90, 90Total no. reflections121042 (10425)228716 (19565)Unique no. reflections32250 (2919)38347 (3695)Multiplicity3.8 (3.6)6.0 (5.3)Completeness (%)0.98 (0.89)0.99 (0.97)\<*I*/σ(*I)*\>10.84 (1.73)14.54 (2.02)Wilson *B*-factor (Å^2^)71.2754.65*R*~merge~0.12 (0.86)0.081 (1.033)*R*~meas~0.14 (1.01)0.089 (1.137)*CC*~1/2~0.99 (0.67)0.998 (0.72)*CC*\*1.00 (0.90)1.00 (0.915)No. reflections used in refinement32240 (2917)38345 (3695)No. reflections used for *R*~free~1584 (148)1891 (173)*R*~work~0.1871 (0.3620)0.1887 (0.2916)*R*~free~0.2297 (0.4022)0.2115 (0.3000)No. non-hydrogen atoms106276045 macromolecules106145990 Ligands12 Protein residues1273750RMS bonds (Å)0.0020.003RMS angles (°)0.480.58Ramachandran favored (%)95.297.4Ramachandran allowed (%)4.82.6Ramachandran outliers (%)00Rotamer outliers (%)0.580.29Clash score6.673.39Average *B*-factor (Å^2^)82.8768.03 Macromolecules82.9168.15 Ligandn.a.68.68 Solvent45.2051.99No. TLS groups2210[^2]

The CyRPA structure ([Figure 3](#fig3){ref-type="fig"}) displays the canonical six-bladed β-propeller (6BBP) fold ([Figure 3A and B](#fig3){ref-type="fig"}) ([@bib5]). Within the β-propeller structure are four intra-sheet disulfide bonds (Cys19-Cys35, Cys90-Cys92, Cys151-Cys169 and Cys229-Cys239) and one inter-sheet disulfide bond (Cys274-Cys298) ([Figure 3A and B](#fig3){ref-type="fig"}). The crystal of uncomplexed CyRPA contains four copies of the protein in the crystallographic asymmetric unit, arranged with approximate 222-point group symmetry ([Figure 3C](#fig3){ref-type="fig"}). Within this tetramer, a pairwise association of CyRPA molecules is mediated by the formation of two eight-strand anti-parallel β-sheets, one (termed sheet '6--6') comprises two copies of the sixth β-sheet of the CyRPA monomer and the second (termed sheet '5--5') comprises two copies of the (adjacent) fifth β-sheet of the CyRPA monomer ([Figure 3C](#fig3){ref-type="fig"}). In each case, formation of the eight-stranded sheet is mediated by the respective outermost strands of the two constituent four-stranded sheets. These dimers of CyRPA monomers then associate with each other *via* the formation of a β-sandwich comprising sheet 6--6 of one CyRPA dimer and sheet 6--6 of the second CyRPA dimer ([Figure 3C](#fig3){ref-type="fig"}). The monomer-monomer interfaces, although extensive, are most likely an artefact of crystallization, as we find no evidence for higher-order association upon SEC of CyRPA. However, we cannot rule out such associations occurring within the hetero-complexes formed by CyRPA and its partner proteins on the surface of the merozoite.

The 6BBP fold is found in a number of enzyme families, as well as in some attachment proteins ([@bib5]). A DALI search ([@bib19]) reveals that the closest structural homologue to CyRPA is the attachment glycoprotein of a henipah virus isolated from Ghanaian bats (PDB entry 4UF7 ([@bib22])), with the next closest homologues being various sialidases of viral, bacterial and mammalian origin ([@bib37]; [@bib26]). CyRPA has up to 16% sequence identity with all such structural homologues found by the DALI search, suggesting only distant evolutionary relationships, if any, with other thus-far structurally-characterized 6BBPs. Nevertheless, given that sialidases appear consistently as the highest-ranking homologues, it is instructive to consider whether CyRPA contains any specific sequence motifs that are characteristic of sialidases and, indeed, whether it has any sialidase activity. We compared the sequence of CyRPA with that of *Clostridium perfringens* NanI sialidase to identify potential conserved residues that might be relevant to sialidase enzyme activity. Localization of these residues on an overlay of structures revealed the absence of any potential active site ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}) ([@bib26]). There are two signature motifs for the active site of all sialidases ([@bib37]; [@bib26]). The first is a set of three conserved arginine residues that coordinate the binding of the carboxylate moiety of sialic acid ([@bib37]; [@bib26]), these residues are located respectively in the loop between the first and second β-sheets, in the loop between the third and fourth strand of the fifth β-sheet and in the loop connecting the second and third strand in the fourth β-sheet. Inspection reveals only one possible equivalent, an arginine at residue 21 in the loop between the first and second β-sheets of CyRPA ([Figure 3B](#fig3){ref-type="fig"}). The second signature motif is a catalytic tyrosine residue located on the loop between the fifth and sixth β-sheets ([@bib37]; [@bib26]). Again, we find no equivalent in CyRPA to this tyrosine. We further tested whether the recombinant CyRPA had sialidase activity, using the fluorogenic substrate 4-methylumbelliferyl *N*-acetyl-α-D-neuraminic acid as a substrate (see Methods), with bacterial sialidase (neuraminidase) from *Arthrobacter ureafaciens* as a positive control ([@bib33]). No significant sialidase activity was detected ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}). We thus conclude that CyRPA is not a functional sialidase.

The antibody-binding region of CyRPA {#s2-4}
------------------------------------

Within the complex, the Fab is oriented (as defined by its long axis) approximately perpendicular to the barrel axis of the 6BBP assembly. The Fab fragment of 8A7 [Figure 3B](#fig3){ref-type="fig"} binds to the region of CyRPA comprising residues from the loop between the second and third strands of the first β-sheet (Gly41, Glu42 and Glu45), residues from the loop between the first and second β-sheets (Asp63, Lys66, Glu67, Thr68, Asp69, Leu70 and Thr71), residues from the loop between the second and third strands of the second β-sheet (Lys91 and Lys99), and residues comprising the N-terminal region of the fourth strand of the second β-sheet (Asn116, Asn117, Ala118 and Glu119) ([Figure 3B](#fig3){ref-type="fig"}, [Figure 4](#fig4){ref-type="fig"}). Comparison with the uncomplexed CyRPA structures reveals only minor changes in rotameric conformation and relative disposition of CyRPA residues at the interface. The antigen interaction involves residues drawn from all six complementary-determining regions (CDRs) of the Fab and buries a total of 1634 Å of the molecular surface across both molecules ([Figure 4A,B and C](#fig4){ref-type="fig"}). The shape complementarity of the interface (*S*~c~ = 0.71) is relatively high for antibody-antigen complexes ([@bib21]), with the surface of CyRPA epitope being predominantly negatively charged ([Figure 4C](#fig4){ref-type="fig"}). The interface itself involves a rich network of approximately nineteen hydrogen bonds ([Figure 4B](#fig4){ref-type="fig"} and [Figure 4---source data 1](#SD1-data){ref-type="supplementary-material"}).10.7554/eLife.21347.008Figure 4.The crystal structure of the Fab 8A7 / CyRPA complex.(**A**) Orthogonal views of the ribbon representation of the complex (CyRPA: *green*, Fab 8A7 light chain: *cyan*; Fab 8A7 heavy chain: yellow. (**B**) Hydrogen bond network within the interface between Fab 8A7 and CyRPA. (**C**) Surface of Fab 8A7 epitope of CyRPA colored according to surface potential (*red* negative, *blue* positive), with the Fab chain colored as in (**A**). Surface potential was computed using CHIMERA ([@bib28]).**DOI:** [http://dx.doi.org/10.7554/eLife.21347.008](10.7554/eLife.21347.008)10.7554/eLife.21347.009Figure 4---source data 1.Deduced hydrogen bonds between CyRPA and Fab 8A7.Hydrogen bonds were computed using the program CONTACT within the CCP4 suite ([@bib7]).**DOI:** [http://dx.doi.org/10.7554/eLife.21347.009](10.7554/eLife.21347.009)10.7554/eLife.21347.010Figure 4---figure supplement 1.Amino acid sequence of anti-CyRPA monoclonal antibody 8A7 Fab fragment for both heavy and light chains.**DOI:** [http://dx.doi.org/10.7554/eLife.21347.010](10.7554/eLife.21347.010)

Discussion {#s3}
==========

The PfRh5/CyRPA/PfRipr complex plays an essential role for invasion of *P. falciparum* into human erythrocytes through binding the receptor basigin ([@bib38]). To provide a structural basis for understanding the function of this complex and its components we have determined the structure of CyRPA in its free form. Additionally, we have determined the structure of CyRPA in complex with a Fab fragment derived from a monoclonal antibody that blocks the growth of the *P. falciparum* parasite to understand the mechanism of inhibition. CyRPA displays a canonical six-bladed β-propeller fold ([@bib5]), and the inhibitory monoclonal is shown to block formation of the PfRh5/CyRPA complex.

The closest structural homologue to CyRPA is the attachment glycoprotein of a henipah virus which binds to ephrinB2 and is important for host cell entry ([@bib22]); however, it also has some similarity to bacterial and viral sialidases all of which have a six-bladed β-propeller fold ([@bib37]; [@bib11], [@bib10], [@bib9]). CyRPA lacks some of the important amino acid motifs required for it to be an active sialidase, and the recombinant form of the protein did not have sialidase activity suggesting it is only distantly related to these enzymes. The PfRh5/CyRPA/PfRipr complex functions together as a conditional expression of CyRPA or PfRipr and blocking of PfRh5 binding to basigin blocks merozoite invasion at the same step ([@bib38]). Merozoites lacking PfRh5/CyRPA/PfRipr complex function can still interact and deform the erythrocyte membrane but they cannot form the pore or discontinuity between the parasite apical end and the erythrocyte membrane through which Ca^2+^ passes ([@bib38]; [@bib39]). Therefore, they do not progress to form a tight junction which requires insertion of the RON complex into the host cell ([@bib39]).

It has been hypothesized that the PfRh5/CyRPA/PfRipr complex is directly involved in forming this pore between the merozoite and erythrocyte membrane ([@bib38]; [@bib39]). The PfRh5 structure has a large coiled-coil domain that has some structural similarity with the N-terminal coiled-coil domain of SipB and other similar proteins ([@bib2]). SipB forms part of the Salmonella type III secretion system that transports effector proteins across the host cell membrane. Additionally, there are six-bladed β--propeller structured proteins, similar to CyRPA, that play a role in the formation of protein translocation channels by bacterial pathogens to inject virulence factors ([@bib25]). Whilst these similarities are tantalizing, the link between the formation of a pore between the merozoite surface and the erythrocyte membrane by the PfRh5/CyRPA/PfRipr is circumstantial and requires further evidence ([@bib38]; [@bib39]).

Our experiments show that CyRPA binds to PfRh5 in the PfRh5/CyRPA/PfRipr tripartite complex and it is likely that it also interacts directly with PfRipr ([@bib38]). The subcellular localization of CyRPA and PfRipr is in the micronemes whereas PfRh5 is at the neck of the rhoptries and the tripartite complex only forms at the interface between the apical end of the merozoite and the erythrocyte membrane. All three proteins are spread over the free merozoite surface but generally CyRPA and PfRipr co-localise whereas PfRh5 does not. This suggests that the PfRh5/CyRPA/PfRipr complex forms during the invasion process when it is required and that its assembly is finely regulated, most likely requiring the function of other unknown proteins. It is also not understood how the PfRh5/CyRPA/PfRipr complex or CyRPA associates with the merozoite membrane as none of these proteins have a transmembrane domain or a GPI anchor ([@bib38]).

The anti-CyRPA monoclonal antibody 8A7 directly abrogates the interaction of CyRPA with PfRh5 and as a result directly blocks merozoite invasion of *P. falciparum* into human erythrocytes. This suggests that the PfRh5 binding site for CyRPA overlaps with (or lies close to) the antibody conformational epitope, defined by residues within the loop between the second and third strands of the first β-sheet, the loop between the first and second β-sheets, and residues at the N-terminus region of the fourth strand of the second β-sheet. The absence of large conformational change within CyRPA upon Fab complexation rules out an allosteric mechanism of abrogating a complex formation with PfRh5. Therefore, blocking of the CyRPA and PfRh5 interaction by antibodies is consistent with a functional PfRh5/CyRPA/PfRipr complex assembling at the interface between the invading merozoite and erythrocyte membrane ([@bib38]).

CyRPA is a highly conserved protein in *P. falciparum* and the antibody binding epitope as well as the remainder of the protein is not under selective pressure. As a result, it is a promising vaccine candidate as antibodies inhibit merozoite invasion in vitro as well as in mice engrafted with human erythrocytes ([@bib32]; [@bib15]). Our results elucidate the structural basis for the binding and inhibition of antibodies to CyRPA that block merozoite invasion. This information will facilitate the development of this candidate in potential vaccines most likely in a combination vaccine with PfRh5 and PfRipr or in the complex form of PfRh5/CyRPA/PfRipr against malaria.

Materials and methods {#s4}
=====================

Protein expression and purification {#s4-1}
-----------------------------------

*Plasmodium falciparum* (3D7) full-length mature CyRPA with the last residues of the three potential glycosylation site motifs mutated to alanine (^116^NNS to NNA, ^293^NTT to NTA and ^299^NRT to NRA) was cloned in to the vector pgpHFT ([@bib43]) and expressed in insect cells as described ([@bib4]), but employing in this instance Sf21 cells rather than Hi5 cells. The supernatant containing the secreted recombinant protein was harvested, centrifuged and passed over an anti-FLAG M2 agarose (Sigma) column. After extensive washing, bound proteins were eluted from the column with FLAG peptide at a concentration of 100 μg/ml, concentrated and then further purified by size-exclusion chromatography (SEC) with a Superdex 200 column (GL 10/300, GE Healthcare) in 25 mM HEPES, 150 mM NaCl, pH 7.2. For crystallization of CyRPA, the tandem hexa-His and FLAG tags were removed by digestion with a TEV protease and purified protein was recovered by Ni-resin and/or SEC. The Fab fragment of anti-CyRPA monoclonal 8A7 (see below for details of monoclonal antibody production and growth inhibition assays) was prepared by digesting the monoclonal antibody parent with papain and then purifying by SEC using a Superdex 200 column (GL 10/300; GE Healthcare). The CyRPA/Fab complex was prepared by combining an excess of CyRPA with the Fab fragment followed by purification of the complex by SEC.

To obtain the amino acid sequence of the VH and VL segments of 8A7 total RNA was isolated from the hybridoma cells following the technical manual of TRIzol Reagent. Total RNA was then reverse transcribed into cDNA using IgG1 kappa-specific anti-sense primers or universal primers following the technical manual of PrimeScriptTM 1st Strand cDNA Synthesis Kit. The antibody fragments of VH and VL were amplified according to the standard operating procedure of rapid amplification of cDNA ends (RACE) of GenScript (New Jersey). Amplified antibody fragments were cloned separately into a standard cloning vector separately. Colony PCR was performed to screen for clones with inserts of correct sizes. No fewer than five colonies with inserts of correct sizes were sequenced for each fragment. The sequences of different clones were aligned and the consensus sequence of these clones was obtained.

Production of monoclonal antibodies and growth inhibition assays {#s4-2}
----------------------------------------------------------------

All procedures with mice were approved by the Walter and Eliza Hall Medical Research Institute Animal Ethics Committee. BALB/c mice were immunized with 20 µg of recombinant CyRPA in Freund\'s complete adjuvant (1st injection; Sigma Aldrich) followed by two subsequent injections of 20 µg CyRPA in Freund\'s incomplete adjuvant (two subsequent injections; Sigma Aldrich, St. Louis, MO) then 40 µg CyRPA in saline and 50 µg CyRPA in saline. Mice were euthanized and spleens harvested using aseptic technique. Spleen cells were fused with myeloma cells. Anti-CyRPA antibody-producing hybridoma cell lines were identified 14 days after fusion, using ELISA with recombinant CyRPA. Positive hybridomas were sub-cloned to obtain monoclonal cell lines. Positive antibodies were subsequently screened by immuno-blot with mature schizonts. Monoclonal antibodies 7A6, 8B9, 3D1, 8A7 and 5B12 were selected for further study and tested to determine if they inhibit *P. falciparum* growth in vitro. 8A7 was used for co-crystallography studies and is isotype IgG1 kappa. Non-inhibitory anti-PfRh5 monoclonal antibody 4G4 and inhibitory anti-PfRipr monoclonal antibody 5G6 were included as controls.

Two cycle growth inhibition assays were performed, using 3D7 strain of *P. falciparum*, as described to determine if the monoclonal antibodies inhibited parasite growth ([@bib18]). Serial dilutions of IgG in PBS, starting at 2 mg/ml were added to *P. falciparum-*infected erythrocytes (3D7) at a parasitaemia of 0.1%. Parasitaemia was counted after 96 hr by flow cytometry and specific growth inhibition calculated relative to parasites grown in non-immune IgG. *P. falciparum* strain 3D7 has been confirmed by whole genome sequencing and was originally obtained from Prof. David Walliker, Edinburgh University.

Immuno-blot screen of anti-CyRPA monoclonal antibodies {#s4-3}
------------------------------------------------------

Synchronized schizont stage 3D7 parasites that expressed HA-tagged CyRPA ([@bib38]) were harvested and erythrocytes lysed using 0.15% saponin. Proteins were solubilized from the saponin pellet with reducing and non-reducing SDS-PAGE sample buffer and separated on 4--12% *bis*-Tris precast NuPAGE gel (Life Technologies, Carlsbad, Ca, USA) then transferred to a nitrocellulose membrane. The membranes were probed with the anti-CyRPA monoclonal antibodies (1/1000) and anti-HA mouse monoclonal (1/1000) as a positive control and proteins detected by enhanced chemiluminescence (ECL, GE Healthcare).

SEC and co-immunoprecipitation {#s4-4}
------------------------------

SEC was performed on an analytical Superdex 200 column or Superose-6 column (24 ml, GE Healthcare) and proteins were eluted with 25 mM HEPES, 150 mM NaCl, pH 7.2 or 25 mM Tris, 150 mM NaCl, pH 8.5. Co-immunoprecipitation of CyRPA with FLAG-tagged PfRh5 was performed using anti-FLAG M2 agarose (Sigma). Briefly, 5 µg FLAG-tagged PfRh5 and 5 µg CyRPA were incubated with 20 µl anti-FLAG M2 agarose beads for 1 hr on ice. After extensive washing with 25 mM Tris, pH 8.5 buffer containing 150 mM NaCl, the bound proteins were eluted with the FLAG peptide at a concentration of 100 μg/ml in the same Tris buffer, analysed by SDS-PAGE and stained with Coomassie Blue R250.

Crystallization and structure determination {#s4-5}
-------------------------------------------

Crystallization trials for both the Fab-bound and the uncomplexed CyRPA protein were initially performed in sitting-drop, 96-well format at 18°C performed at the CSIRO Collaborative Crystallization Centre (Parkville, Australia), followed by in-house refinement. Diffracting crystals of CyRPA were finally obtained from hanging drops containing 9% PEG1000, 9% PEG8000, 0.25 M potassium iodide and 50 mM potassium thiocyanate. Diffracting crystals of CyRPA/Fab complex were finally obtained from hanging drops containing 11% PEG5000 monomethyl ether and 0.2M sodium acetate, pH 5.5. For data collection, crystals were transferred to cryo-protection solutions (12% PEG1000, 12% PEG8000, 0.25 M potassium iodide, 50 mM potassium thiocyanate and 25% ethylene glycol for CyRPA crystals; 15% PEG5000 monomethyl ether and 0.2M sodium acetate, pH 5.5% and 25% ethylene glycol for CyRPA/Fab complex crystals) and cryo-cooled by plunging into liquid nitrogen. X-ray diffraction data were collected on beamline MX2 at the Australian Synchrotron at a temperature of \~100 K ([@bib24]).

Diffraction data were processed and scaled with XDS ([@bib20]). Resolution limits were set to 3.09 Å for the native CyRPA crystal data and to 2.44 Å for the CyRPA/Fab complex crystal data. For the structure solution of CyRPA/Fab complex, initial phases were obtained by molecular replacement using PHASER ([@bib23]) with the structure of a murine Fab fragment (PDB code: 5L9D; unpublished) as a search model within PHASER ([@bib20]). Model building and refinement then continued within PHENIX ([@bib1]), with automated building and morphing routines leading to a model comprising the majority of the CyRPA/Fab sequence. Further rounds of refinement and manual rebuilding were undertaken using PHENIX ([@bib1]) and COOT ([@bib16]). The structure of the native CyRPA was solved by molecular replacement with coordinates of CyRPA---derived from the refined CyRPA/Fab structure---used as a search model. Data processing and refinement statistics for both structures are provided in [Table 1](#tbl1){ref-type="table"}.

Sialidase assay {#s4-6}
---------------

Sialidase (i.e., neuraminidase) activity was assayed using the fluorogenic substrate 4-methylumbelliferyl *N*-acetyl-α-D-neuraminic acid sodium salt (4 mU-NeuNAc). Reaction volumes (100 μl) containing 4 mU-NeuNAc (100 μM) at pH 5.0 (50 mM citrate, 150 mM NaCl), pH 6.5 (50 mM MES, 150 mM NaCl) and pH 8.0 (50 mM Tris-HCl, 150 mM NaCl) were incubated with BSA (5 μg/ml), CyRPA (5.0 μg/ml) or *Arthrobacter ureafaciens* sialidase (neuraminidase) (Sigma-Aldrich N3786, 0.1 μg/ml) for 4 hr at 37°C. Each reaction was quenched with glycine buffer (900 μl, 1 M, pH 10) and fluorescence measured (λ~ex~ = 365 nm, λ~em~ = 445 nm) on a Cary Eclipse fluorimeter (Agilent Technologies). These values, obtained in triplicate, were normalized with respect to the fluorescence measured for 10 μM 4-methylumbelliferone in glycine buffer (0.9 M, pH 10) to determine the completeness of each reaction.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Structural basis for inhibition of erythrocyte invasion by antibodies to *Plasmodium falciparum* protein CyRPA\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, one of whom Stephen C. Harrison (Reviewer \#1), is a member of our Board of Reviewing Editors, and the evaluation has been overseen by John Kuriyan as the Senior Editor.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

Chen at all investigate the structure and inhibition of PfCyRPA, an essential protein for the invasion of erythrocytes by *Plasmodium falciparum*. They show that CyRPA interacts directly with RH5. They identify monoclonal antibodies with growth inhibitory activity and present data suggesting that one of these prevents CyRPA from interacting with Rh5. They then present the structure of CyRPA, both alone and in complex with one of these antibodies. This is an interesting piece of work that analyzes an important protein and putative vaccine candidate.

Major points needing attention/revision:

1\) The structural biology is generally convincing, but the data cut-off used is too generous. The values for I/sig(I) and CC~1/2~ for the outer shell are extremely low. In addition, the overall *R~merge~*is very high, and the *R~merge~* in the outer shell is exceptionally high. The structure of the complex is actually the better of the two; the claimed resolution is 2.26 Å, but even 2.5Å (a more conservative cutoff) is accurate enough for the conclusions the authors draw. The data processing and refinement need to be repeated using more appropriate resolution cutoffs, and the new, lower, resolution should be reported in the main text.

2\) In the parasite inhibition studies, a control antibody should be included for comparison. For a reader to judge how effective these CyRPA antibodies are at inhibiting invasion, it would also be valuable to include one or more other inhibitory antibodies (i.e. those that bind to PfRH5) included in this analysis so that the study would go beyond a demonstration of some inhibitory potential and allow the reader to see how inhibitory potency of this mAb compares with those of mAbs targeting other leading vaccine candidates. The field generally lacks this comparative analysis, which makes deciding which vaccine candidates to take forward challenging.

3\) The authors show data to suggest 8A7 directly prevents RH5 binding to CyRPA, while 7A6 does not ([Figure 2C and D](#fig2){ref-type="fig"}). While this conclusion is likely, the data presented are not as convincing as they should be. (a) It appears that the binding of RH5 and CyRPA is weak as indicated by the pulldown experiments ([Figure 1C](#fig1){ref-type="fig"}) and the coelution profile (1B). Given the weak affinity it is plausible that the concentrations of RH5 and CyRPA used in the inhibition experiment (2C) might not have allowed complex formation, leading to an inaccurate conclusion that the inhibitory effect of 8A7 comes from blocking the interaction. (b) The authors use 7A6 as a control to demonstrate this antibody does not disrupt the complex and does not prevent parasite growth. Because 7A6 does not bind folded CyRPA and therefore cannot possibly disrupt binding, it is not a suitable control.

3\) The authors state that they find no evidence for higher-order association from SEC of CyRPA. [Figures 1B](#fig1){ref-type="fig"} and [2C](#fig2){ref-type="fig"} seem to indicate otherwise. RH5 has a larger mass than CyRPA but elutes later than CyRPA. Thus, CyRPA appears to elute far earlier than a monomer would, and one might conclude that it is an oligomer. Additional data should be provided to examine the oligomeric state in solution. Oligomerization is important for complex formation of a number of parasite proteins (reviewed in Paing, et al. PLOS Pathogens (2014) 10(6): e1004120). It might be prudent to cite this and other related work. Finally, how does the 8A7 epitope correlate with the putative tetrameric contacts in CyRPA?

4\) It would be good to have a direct measurement, for example by SPR, of the CyRPA:RH5 interaction, in the presence and absence of the antibody. The relative affinities and on- and off- rates for these interactions will probe how this antibody-mediated inhibition works and show whether the kinetics of the two binding events are compatible with the disruption of a pre-formed CyRPA:CyRPA complex.

5\) Please provide a DNA sequence for the entire Fab (e.g., in a supplemental figure), as it is important for assessing the structure. (Otherwise, a reader will need to consult the deposited PDB file, which can be awkward.)
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Author response

Major points needing attention/revision:

1\) The structural biology is generally convincing, but the data cut-off used is too generous. The values for I/sig(I) and CC~1/2~ for the outer shell are extremely low. In addition, the overall R~merge~ is very high, and the R~merge~ in the outer shell is exceptionally high. The structure of the complex is actually the better of the two; the claimed resolution is 2.26 Å, but even 2.5Å (a more conservative cutoff) is accurate enough for the conclusions the authors draw. The data processing and refinement need to be repeated using more appropriate resolution cutoffs, and the new, lower, resolution should be reported in the main text.

We have reprocessed the data, refined the structure and modified [Table 1](#tbl1){ref-type="table"} as requested. CyRPA is now a resolution of 3.09 Å. CyRPA/Fab complex is now 2.44 Å. These are reported in the main text.

2\) In the parasite inhibition studies, a control antibody should be included for comparison. For a reader to judge how effective these CyRPA antibodies are at inhibiting invasion, it would also be valuable to include one or more other inhibitory antibodies (i.e. those that bind to PfRH5) included in this analysis so that the study would go beyond a demonstration of some inhibitory potential and allow the reader to see how inhibitory potency of this mAb compares with those of mAbs targeting other leading vaccine candidates. The field generally lacks this comparative analysis, which makes deciding which vaccine candidates to take forward challenging.

We have now included an inhibitory anti-Ripr monoclonal antibody 5G6 as a positive control and a non-inhibitory anti-Rh5 monoclonal antibody 4G4 as a negative control.

3\) The authors show data to suggest 8A7 directly prevents RH5 binding to CyRPA, while 7A6 does not ([Figure 2C and D](#fig2){ref-type="fig"}). While this conclusion is likely, the data presented are not as convincing as they should be. (a) It appears that the binding of RH5 and CyRPA is weak as indicated by the pulldown experiments ([Figure 1C](#fig1){ref-type="fig"}) and the coelution profile (1B). Given the weak affinity it is plausible that the concentrations of RH5 and CyRPA used in the inhibition experiment (2C) might not have allowed complex formation, leading to an inaccurate conclusion that the inhibitory effect of 8A7 comes from blocking the interaction. (b) The authors use 7A6 as a control to demonstrate this antibody does not disrupt the complex and does not prevent parasite growth. Because 7A6 does not bind folded CyRPA and therefore cannot possibly disrupt binding, it is not a suitable control.

The concentration of PfRh5 and CyRPA used in [Figure 2C and D](#fig2){ref-type="fig"} are similar to those used in [Figure 1B](#fig1){ref-type="fig"} and therefore Rh5/CyRPA complex should form if anti-CyRPA 8A7 doesn't block the interaction, as in the case of [Figure 2D](#fig2){ref-type="fig"}. Thus we are confident in the conclusion we have made.

For panel 2D, we agree that anti-CyRPA antibody 7A6 that doesn't bind to folded CyRPA is not the perfect control. Nevertheless, we have demonstrated that without a blocking antibody, Rh5 would form a complex with CyRPA.

However, to address the reviewers comments we have screened a larger number of monoclonals to both PfRh5 and CyRPA. All of the CyRPA non-inhibitory monoclonals produced react to internal epitopes as is the case for 7A6 so were not useful as extra controls required by the reviewers. We have retained the experiment using 7A6 as a control as we believe it is relevant. However, we have identified a monoclonal antibody to PfRh5 (Rh5 4G4), which is non-inhibitory, and this binds to the PfRh5/CyRPA complex but does not disrupt it. This adds an additional control requested in [Figure 2](#fig2){ref-type="fig"} panel D.

3\) The authors state that they find no evidence for higher-order association from SEC of CyRPA. [Figures 1B](#fig1){ref-type="fig"} and [2C](#fig2){ref-type="fig"} seem to indicate otherwise. RH5 has a larger mass than CyRPA but elutes later than CyRPA. Thus, CyRPA appears to elute far earlier than a monomer would, and one might conclude that it is an oligomer. Additional data should be provided to examine the oligomeric state in solution. Oligomerization is important for complex formation of a number of parasite proteins (reviewed in Paing, et al. PLOS Pathogens (2014) 10(6): e1004120). It might be prudent to cite this and other related work. Finally, how does the 8A7 epitope correlate with the putative tetrameric contacts in CyRPA?

The CyRPA we used in the experiments is monomeric based on SEC analyses. In [Figure 1B](#fig1){ref-type="fig"}, CyRPA formed a complex with Rh5 and therefore was eluted in the earlier fractions compared to free CyRPA. In [Figure 2C](#fig2){ref-type="fig"}, antibody 8A7 bound to CyRPA, disrupting the Rh5/CyRPA complex, and CyRPA observed in the earlier fractions is in complex with the antibody.

Thus, in [Figures 1B](#fig1){ref-type="fig"} and [2C](#fig2){ref-type="fig"}, CyRPA doesn't elute earlier than Rh5 and in fact CyRPA is indeed eluted slightly later than Rh5 as presented in [Figure 2D](#fig2){ref-type="fig"}.

We have altered 1B and 2C figure legends to more fully explain this.

The antibody 8A7 epitope lies outside the interface of the tetrameric CyRPA in the crystallographic asymmetric unit.

4\) It would be good to have a direct measurement, for example by SPR, of the CyRPA:RH5 interaction, in the presence and absence of the antibody. The relative affinities and on- and off- rates for these interactions will probe how this antibody-mediated inhibition works and show whether the kinetics of the two binding events are compatible with the disruption of a pre-formed CyRPA:CyRPA complex.

We agree that SPR would be very useful to have and before submitting the initial manuscript we tried to get such data with which we were confident. However, using SPR it can be very difficult to study protein-protein interaction (apart from antibody-antigen interaction). As the reviewers would know the most difficult part is regeneration of the chip to allow multiple injections to derive kinetic data. Many proteins don't survive the regeneration conditions and this was our major problem. Furthermore, it is very difficult to control how the protein is coupled to a chip and to find a valid control. As said above we attempted SPR to obtain the data requested by the reviewer but were unable to generate reliable data that we were comfortable in publishing.

Despite this we believe that our SEC data shows that PfR5 and CyRPA form a stable complex. As stated above the CyRPA we have generated appears to be a monomer.

5\) Please provide a DNA sequence for the entire Fab (e.g., in a supplemental figure), as it is important for assessing the structure. (Otherwise, a reader will need to consult the deposited PDB file, which can be awkward.)

We have included a supplemental figure for the sequence of the entire Fab fragment.
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